COEP - NASDAQ

Coeptis Therapeutics, Inc.

COEP·NASDAQ

$16.40

+0.0000%

HealthcareBiotechnology

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$57.63M

EPS-2.8100

P/E Ratio-5.84

Earnings Date06/03/2026

19.84M

Assets

123%

3Y+151.0%

5Y+6503.0%

10Y+42185.0%

2.09M

Total Liabilities

-59%

3Y-40.0%

5Y-62.0%

10Y+571.0%

17.75M

Total Equity

359%

3Y+299.0%

5Y-445.0%

10Y-6825.0%

Coeptis Therapeutics, Inc. Funding & Solvency Profile

COEP · NASDAQ

Current Assets

Cash & Cash Equivalents5.67M

Net Receivables7.35K

Inventory0.00

Other Current Assets0.00

Total Current Assets7 M

Non-Current Assets

Property, Plant & Equipment18.40K

Goodwill & Intangible Assets361.25K

Long-Term Investments7.86M

Other Non-Current Assets4.25M

Total Non-Current Assets12 M

Total Assets

19.84M

Financial Health Analysis

Current Ratio

4.16x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

6 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

37% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Coeptis Therapeutics, Inc. Balance Sheet

COEP • NASDAQ

Coeptis Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2005	Dec 2004
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	5.7M	532.9K	1.5M	3.8M	2.2M	203K	505.0	0.0	153.6K	383.0
Short-Term Investments	676.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	6.4M	532.9K	1.5M	3.8M	2.2M	203K	505.0	0.0	153.6K	383.0
Net Receivables	7.3K	0.0	39K	8.1K	0.0	21.8K	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	8.1K	0.0	21.8K	0.0	0.0	0.0	0.0
Other Receivables	7.3K	0.0	39K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	991.9K	518.4K	241.6K	142.4K	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	7.4M	1.1M	1.7M	3.9M	2.2M	224.8K	505.0	0.0	153.6K	383.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	18.4K	59.8K	108.9K	71.5K	31.9K	73.7K	0.0	0.0	0.0	0.0
Intangible Assets	361.3K	541.9K	2.6M	3.6M	0.0	0.0	0.0	0.0	0.0	46.5K
Goodwill & Intangible Assets	361.3K	541.9K	2.6M	3.6M	0.0	0.0	0.0	0.0	0.0	46.5K
Long-Term Investments	7.9M	5.7M	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	4.3M	1.6M	158.3K	348.3K	4.6M	2K	171K	80K	0.0	0.0
Total Non-Current Assets	12.5M	7.9M	6.3M	4M	4.6M	75.7K	171K	80K	0.0	46.5K
Other Assets	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
Total Assets	19.8M	8.9M	8.1M	7.9M	6.8M	300.5K	171.5K	80K	153.6K	46.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	888.8K	1.3M	1.4M	99K	134.1K	1.6M	450.0	0.0	55.2K	215.9K
Accounts Payable	888.8K	1.3M	1.4M	99K	134.1K	1.6M	450.0	0.0	55.2K	215.9K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-55.2K	-215.9K
Accrued Expenses	0.0	736.9K	0.0	0.0	199.1K	732.1K	0.0	0.0	0.0	0.0
Short Term Debt	118.9K	1.2M	1M	1.9M	2.4M	1.9M	152.6K	62.1K	650K	95K
Capital Lease Obligations (Current)	0.0	42.3K	0.0	0.0	14.7K	41.6K	0.0	0.0	0.0	0.0
Deferred Revenue	599.5K	0.0	0.0	0.0	0.0	1M	2.8K	0.0	0.0	0.0
Other Current Liabilities	161.1K	1.3M	556K	182K	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	1.8M	4.5M	3M	2.2M	2.8M	5.3M	155.9K	62.1K	705.2K	310.9K
NON-CURRENT LIABILITIES
Long Term Debt	150K	150K	150K	150K	1.7M	150K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	167.6K	359.3K	557.2K	1.1M	0.0	-1.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	317.6K	528.1K	768.4K	1.3M	1.7M	164.7K	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	61.2K	61.2K	14.7K	14.7K	56.3K	0.0	0.0	0.0	0.0
Total Liabilities	2.1M	5M	3.8M	3.5M	4.4M	5.4M	155.9K	62.1K	705.2K	310.9K
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	-247.2K	0.0	0.0	0.0	0.0	0.0
Common Stock	575.0	212.0	3.5K	2K	3.6K	2.5K	25K	25K	1.6K	3.8K
Additional Paid-In Capital	127.2M	103M	91.7M	70.5M	30.1M	9M	0.0	0.0	0.0	0.0
Retained Earnings	-110M	-98.2M	-87.4M	-66.1M	-27.6M	-14.1M	-9.3K	-7.1K	-3.3M	-2.9M
Other Total Stockholders' Equity	0.0	-1.6M	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	2.7M
Total Stockholders' Equity	17.2M	3.2M	4.3M	4.5M	2.4M	-5.1M	15.7K	17.9K	-551.7K	-264K
Total Equity	17.8M	3.9M	4.3M	4.5M	2.4M	-5.1M	15.7K	17.9K	-551.7K	-264K
Minority Interest	506.2K	682.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	19.8M	8.9M	8.1M	7.9M	6.8M	300.5K	171.5K	80K	153.6K	46.9K
Total Investments	8.5M	5.7M	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	268.9K	1.4M	1.2M	2.1M	4.1M	2.1M	152.6K	62.1K	650K	95K
Net Debt	-5.4M	866.2K	-244.9K	-1.7M	1.9M	1.9M	152.1K	62.1K	496.4K	94.6K
Shares Outstanding	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840	3,513,840

SEC Filings

COEP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 01, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 07, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 04, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 16, 2026	January 12, 2026	2026	View Filing
S-4/A S-4/A (Amended) N/A	December 22, 2025	December 22, 2025		View Filing

Showing 1 to 10 of 116 filings

Related Guides

Blog Categories

Continue your COEP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.